Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer
OCGN has more than doubled off its 52-week low of $0.515.
Summary
Ocugen, Inc. has appointed Rita Johnson-Greene as its new Chief Financial Officer, effective February 9, 2026, with a compensation package including a $440,000 base salary, a $90,000 sign-on bonus, and significant equity awards.
Key Events · Executive and Board Changes · OCGN
-
New Chief Financial Officer Appointed
Rita Johnson-Greene has been appointed as Chief Financial Officer, effective February 9, 2026, and will become Principal Financial Officer after the 2025 10-K filing.
-
Experienced Financial Leader Joins
Ms. Johnson-Greene previously served as COO of Alliance for Regenerative Medicine and held leadership roles at bluebird bio, Spark Therapeutics, and AstraZeneca.
-
Compensation Package Detailed
Her compensation includes an annual base salary of $440,000, a target annual bonus of up to 45% of base salary, and a one-time sign-on bonus of $90,000.
-
Significant Equity Awards Granted
She received an option to purchase 750,000 shares and 500,000 restricted stock units (RSUs), both vesting over three years.
Analysis · OCGN · Life Sciences
Ocugen, Inc. announced the appointment of Rita Johnson-Greene as its new Chief Financial Officer, a critical leadership role for a life sciences company with ongoing clinical trials and recent capital raises. Ms. Johnson-Greene brings extensive experience from previous roles at Alliance for Regenerative Medicine, bluebird bio, Spark Therapeutics, and AstraZeneca, which is valuable for guiding the company's financial strategy. The compensation package, including a substantial equity grant, is designed to attract and retain experienced talent, signaling the company's commitment to strengthening its executive team following recent financing activities.
At the time of this filing, OCGN was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $436.1M. The 52-week trading range was $0.52 to $1.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.